Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. - Wikidata - wikimedia - TriplyDB

Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.

Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.

http://www.wikidata.org/entity/Q33429803

about

Implantable miniature telescope (IMT) for vision loss due to end-stage age-related macular degeneration Nutritional supplements for age-related macular degeneration Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors.Street-crossing decision-making: a comparison between patients with age-related macular degeneration and normal vision.Improving function in age-related macular degeneration: a randomized clinical trial Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up.Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration A low-vision rehabilitation program for patients with mild cognitive deficits Improved assessment of laser-induced choroidal neovascularization The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders Differential effects of the estrogen receptor agonist estradiol on toxicity induced by enzymatically-derived or autoxidation-derived oxysterols in human ARPE-19 cells.Patients' knowledge and perspectives on wet age-related macular degeneration and its treatment.Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo.Transcriptome analysis and molecular signature of human retinal pigment epithelium.Cone structure in subjects with known genetic relative risk for AMD.Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye.New grading criteria allow for earlier detection of geographic atrophy in clinical trials Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study.Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells.Projected changes in age-related macular degeneration and driving license holders in Finland Complement regulatory protein CD46 protects against choroidal neovascularization in mice.Quantification of visual field loss in age-related macular degeneration.Identification of miRNA signatures during the differentiation of hESCs into retinal pigment epithelial cells.In vivo imaging of photoreceptor disruption associated with age-related macular degeneration: A pilot study.Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration Zinc supplementation inhibits complement activation in age-related macular degeneration.Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration.Improving function in age-related macular degeneration: design and methods of a randomized clinical trial.Recent advances in ophthalmic drug delivery.Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry.An Agent-Based Modeling Template for a Cohort of Veterans with Diabetic Retinopathy.Age-related macular degeneration and the other double helix. The Cogan Lecture.The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Targeting Neovascularization in Ischemic Retinopathy: Recent Advances Phototoxic action spectrum on a retinal pigment epithelium model of age-related macular degeneration exposed to sunlight normalized conditions Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD Foveal morphology affects self-perceived visual function and treatment response in neovascular age-related macular degeneration: a cohort study.

P2860

Q24194356-0391DEC1-E7AC-4255-B260-AB557A21B32A Q24603642-9E521CE4-D273-4B56-9899-AEBC1E9B882E Q28383429-58A5AAA0-EB4B-43F3-BCE9-F7DD4D80CFD4 Q30239897-EFDE3544-5758-47C4-82E4-A99C098515EF Q30457737-968562B8-0683-43C2-B7C2-690035A7E264 Q30542436-82638ADF-AA64-45D7-9B7D-FFB8788BD31E Q30829406-8A260FA0-D3F5-4C98-AF25-43A992112924 Q31015035-1AFE06FE-F7A1-452E-982B-A75D47DE8130 Q33355743-92755F28-A092-4A7F-9FF3-03F542E8870F Q33606410-B441C1E3-2374-45C5-8C18-0E76778CCA98 Q33733227-141857E1-AB97-40A2-942B-619A606716E6 Q33795949-6571F4B0-6BAE-413B-A3F0-B95F22F5EA95 Q33837372-642CD9FD-60B7-4FCA-9060-D782DC5271CE Q33840832-424B0C0F-07C1-4027-B4B3-731C4DDCFC7F Q33878301-610C38F0-FDAB-421C-977F-7D21EF2C034F Q33953252-27126A3B-9857-4D67-BFA3-ED07D1510042 Q34035522-0135A69C-808D-4F55-97A1-F234E0BC2F0E Q34062089-60CCA3C7-D5DB-4604-9C3C-3BA99DBCF6D7 Q34062494-0C2233C9-D61A-44EC-8EF1-8E6E60710D60 Q34092454-B82B8ECF-1E1D-4536-BC16-3CA06240EA41 Q34108927-F8D80A4E-908D-42D6-9214-5C885390E337 Q34208163-C02D2259-08F9-45B5-B93D-F4BF31EFFB78 Q34274040-3FA72430-FCE7-49E7-8F66-2C7FB33E4287 Q34299745-99C89BA8-1102-4163-92DA-694BCB4CAD27 Q34328442-F456E3A3-5565-4FCC-B425-0BF35E243618 Q34357703-0DF0B4BD-CB62-40EE-96B7-9B64EA5A8070 Q34397034-BA3746E5-01DA-4440-AF0A-185FFAF7F3AE Q34474600-23EECDAD-B1F9-44B1-91F4-D613EE70A032 Q34506404-A4D811F9-36A6-4590-89D3-9B6CE1A00FB0 Q34518507-55EE1470-26C6-4E8F-8880-2CBD629D43FE Q34556526-0B1DCB3D-A5B8-4698-B7F4-A26545F4E68B Q34636338-278BF09D-76DC-41C9-824E-08741C16BC84 Q34645582-7E43E755-6443-43C2-A421-FB7F17CCE95B Q34785594-70F84405-AAF2-4D6B-B883-6ABD8D0550AD Q34824054-0106ED7A-3658-467D-852A-A42FF124ABF6 Q34882377-D5A03BF0-A656-4E6B-AEB7-9AD00547626D Q34972210-AAC0D5F5-8342-4B14-B91C-2CE45D232DCE Q34994172-46A393A6-22B8-42AA-9A44-D572FF335101 Q35027712-67A43198-08D5-4B7A-ADAE-24101B84A8DB Q35117715-AF373EB7-653D-420D-BCA0-286545054352

P2860

Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.

http://www.wikidata.org/entity/Q33429803

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Forecasting age-related macula ...... tial impact of new treatments.

@ast

Forecasting age-related macula ...... tial impact of new treatments.

@en

type

label

Forecasting age-related macula ...... tial impact of new treatments.

@ast

Forecasting age-related macula ...... tial impact of new treatments.

@en

prefLabel

Forecasting age-related macula ...... tial impact of new treatments.

@ast

Forecasting age-related macula ...... tial impact of new treatments.

@en

P1433

Q33429803-B06CA89D-16C3-49A8-8766-9881C83D3F0B

P1476

Q33429803-A8668FE0-BEF3-4D77-93BD-0E42D4F1866B

P2093

Q33429803-26B68702-AE41-43F7-A8CC-2EE259787A8E

Q33429803-2C20417F-2627-475A-A5BC-C52672A070F0

Q33429803-4B9D331B-F71D-4C75-A6BE-225CB5CDD27E

Q33429803-66BC32C9-4C53-4AAA-B5EB-96AF1F70B6F2

Q33429803-860BE4D8-A7D0-4B06-8BE3-CCAA429AD02B

Q33429803-8F0B96E6-7F92-4311-9688-2257CEC9AB37

Q33429803-AFB55A9A-ADE4-434B-9620-21EF678A3F76

P304

Q33429803-608FC757-0B7E-44D5-86EF-075638AC3256

P31

Q33429803-C8251D54-F3B0-499D-9603-14D512F3AD0A

P356

Q33429803-26892558-29F5-4F73-9765-5ECA36D7B2AA

P407

Q33429803-12EAC61A-D649-485E-B39A-7C9A73BD622F

P433

Q33429803-7AB2566E-B794-4930-9222-3D014DB7111B

P478

Q33429803-42085C25-2BC9-4F2A-891B-35153641CF20

P577

Q33429803-DD024CBC-9E84-44E5-91BD-FB55F297EC01

P5875

Q33429803-F8CF80A5-FABF-4E7C-9FC9-977B23D52BCB

P698

Q33429803-03B47D74-1CC2-49CE-88FA-F5C0692AB243

P356

ARCHOPHTHALMOL.2009.58

P1433

JAMA Ophthalmology

P1476

Forecasting age-related macula ...... tial impact of new treatments.

@en

P2093

Amanda A Honeycutt

http://www.w3.org/2001/XMLSchema#string

David B Rein

http://www.w3.org/2001/XMLSchema#string

Jinan Saaddine

http://www.w3.org/2001/XMLSchema#string

John S Wittenborn

http://www.w3.org/2001/XMLSchema#string

Sarah B Lesesne

http://www.w3.org/2001/XMLSchema#string

Vision Health Cost-Effectiveness Study Group

http://www.w3.org/2001/XMLSchema#string

Xinzhi Zhang

http://www.w3.org/2001/XMLSchema#string

P304

533-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHOPHTHALMOL.2009.58

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24276266

http://www.w3.org/2001/XMLSchema#string

P698

19365036

http://www.w3.org/2001/XMLSchema#string